Abselion launches Protein G antibody quantification kit for benchtop platform
Cambridge-based Abselion has introduced a Protein G Total Antibody Quantification Kit for its Amperia benchtop platform, extending the system’s analytical capabilities beyond existing Protein A-based formats. The kit enables researchers to quantify antibodies across a broader spectrum of IgG subclasses and species, addressing measurement gaps in humanised antibodies, rodent IgGs, and engineered variants.
Electrochemical detection approach streamlines titre measurement
The assay employs pre-coated sensor strips that directly capture antibodies from samples through Protein G binding. Following incubation, a labelled detection molecule occupies remaining Fc-binding sites on the sensor surface. The system generates an electrical signal inversely proportional to antibody concentration – higher antibody levels result in fewer available binding sites and consequently lower signal output.
The Amperia platform delivers quantitative results without requiring optical or fluidic systems, distinguishing it from techniques such as bio-layer interferometry and surface plasmon resonance. These conventional methods often demand specialised laboratory infrastructure and technical expertise, creating potential bottlenecks in analytical workflows.
Ready-to-use format supports process development applications
The kit arrives with Protein G-coated sensor strips, assay plates, detection reagents, and buffers in a ready-to-use configuration. Integrated software provides step-by-step protocol guidance, enabling researchers to generate titre data without extensive assay development or operator training. The format accommodates purified and partially purified antibody samples in research and process development contexts.
“Antibody-based research and development often involves a wide variety of formats, subclasses, and species. Having the flexibility to choose the most appropriate assay without adjusting workflows can simplify decision-making and improve efficiency,” said Dr Ruizhi Wang, CEO and founder of Abselion. “Expanding our antibody quantification offering with Protein G allows us to better support scientists working with a broader range of antibody formats, and reflects our ongoing focus on making practical, application-driven tools more accessible.”
The development represents Abselion’s continued investment in its Redox Electrochemical Detection technology platform, which the Cambridge-based company positions as an alternative to laboratory-
based analytical instruments for biomolecule quantification in therapeutic development settings.
For more information, visit: https://www.abselion.com/assay-kits
Digital issue: Please click here for more information
